急性血管性脑损伤患者发热预防:INTREPID随机临床试验
这项开放标签随机临床试验在7国43个重症监护室纳入686例急性血管性脑损伤患者,比较自动体表温度管理装置预防发热与标准治疗。预防组每日平均发热负荷显著低于标准治疗组,但3个月功能恢复无显著差异,主要不良事件在预防组更常见。
要点
- 预防组每日平均发热负荷为0.37°C-hour,标准治疗组为0.73°C-hour,差异有统计学意义。
- 3个月功能恢复(改良Rankin量表移位分析)在两组间无显著差异,比值比为1.09。
- 预防组主要不良事件发生率为82.2%,标准治疗组为75.9%。
核心结论
- 在急性血管性脑损伤患者中,使用自动体表温度管理装置进行预防性正常体温管理有效降低了发热负荷,但未改善功能结局。
研究设计与样本
- 开放标签随机临床试验,采用盲法结局评估;原计划纳入1176例,实际纳入686例危重卒中患者,来自7个国家43个重症监护室,入组时间为2017年3月至2021年4月,末次随访日期为2022年5月12日。
- 预防组339例,目标体温37.0°C持续14天或至重症监护室出院,使用自动体表温度管理装置;标准治疗组338例,在体温≥38°C时接受标准化分级发热治疗。
- 主要分析人群为677例(缺血性卒中254例、脑出血223例、蛛网膜下腔出血200例;女性345例[51%];中位年龄62岁),433例(64%)完成12个月研究随访。
主要发现
- 预防组每日平均(标准差)发热负荷为0.37(1.0)°C-hour(范围0.0-8.0°C-hour),标准治疗组为0.73(1.1)°C-hour(范围0.0-10.3°C-hour),差异为-0.35(95%CI,-0.51至-0.20),P<.001。
- 按卒中亚型分析,主要结局的组间差异分别为:缺血性卒中-0.10(95%CI,-0.35至0.15),脑出血-0.50(95%CI,-0.78至-0.22),蛛网膜下腔出血-0.52(95%CI,-0.81至-0.23),均P<.001(Wilcoxon秩和检验)。
- 3个月功能恢复无显著差异:中位改良Rankin量表评分两组均为4.0,功能结局有利移位的比值比为1.09(95%CI,0.81至1.46),P=.54。
- 主要不良事件在预防组发生率为82.2%,标准治疗组为75.9%;其中感染分别为33.8% vs 34.5%,心脏疾病分别为14.5% vs 14.0%,呼吸系统疾病分别为24.5% vs 20.5%。
局限性
- 计划中期分析显示主要次要终点无效后停止入组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Fever is associated with worse outcomes in patients with stroke, but whether preventing fever improves outcomes is unclear. OBJECTIVE: To determine whether fever prevention after acute vascular brain injury is achievable and impacts functional outcome. DESIGN, SETTING, AND PARTICIPANTS: Open-label randomized clinical trial with blinded outcome assessment that enrolled 686 of 1176 planned critically ill patients with stroke at 43 intensive care units in 7 countries from March 2017 to April 2021 (last date of follow-up was May 12, 2022). INTERVENTION: Patients randomized to fever prevention (n = 339) were targeted to 37.0 °C for 14 days or intensive care unit discharge using an automated surface temperature management device. Standard care patients (n = 338) received standardized tiered fever treatment on occurrence of temperature of 38 °C or greater. MAIN OUTCOMES AND MEASURES: Primary outcome was daily mean fever burden: the area under the temperature curve above 37.9 °C (total fever burden) divided by the total number of hours in the acute phase, multiplied by 24 hours (°C-hour). The principal secondary outcome was 3-month functional recovery by shift analysis of the 6-category modified Rankin Scale, which is scored from 0 (no symptoms) to 6 (death). Major adverse events included death, pneumonia, sepsis, and malignant cerebral edema. RESULTS: Enrollment was stopped after a planned interim analysis demonstrated futility of the principal secondary end point. In total, 686 patients were enrolled, and 9 were consented but not randomized, leaving a primary analysis population of 677 patients (254 ischemic stroke, 223 intracerebral hemorrhage, 200 subarachnoid hemorrhage; 345 were female [51%]; median age, 62 years) with 433 (64%) completing the study through 12 months. Daily mean (SD) fever burden was significantly lower in the fever prevention group (0.37 [1.0] °C-hour; range, 0.0-8.0 °C-hour) compared with the standard care group (0.73 [1.1] °C-hour; range, 0.0-10.3 °C-hour) (difference, -0.35 [95% CI, -0.51 to -0.20]; P < .001). Between-group differences for the primary outcome by stroke subtype were -0.10 (95% CI, -0.35 to 0.15) for ischemic stroke, -0.50 (95% CI, -0.78 to -0.22) for intracerebral hemorrhage, and -0.52 (95% CI, -0.81 to -0.23) for subarachnoid hemorrhage (all P < .001 by Wilcoxon rank-sum test). There was no significant difference in functional recovery at 3 months (median modified Rankin Scale score, 4.0 vs 4.0, respectively; odds ratio for a favorable shift in functional outcome, 1.09 [95% CI, 0.81 to 1.46]; P = .54). Major adverse events occurred in 82.2% of participants in the fever prevention group vs 75.9% in the standard care group, including 33.8% vs 34.5% for infections, 14.5% vs 14.0% for cardiac disorders, and 24.5% vs 20.5% for respiratory disorders. CONCLUSIONS AND RELEVANCE: In patients with acute vascular brain injury, preventive normothermia using an automated surface temperature management device effectively reduced fever burden but did not improve functional outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02996266.
引用
- Greer DM, Helbok R, Badjatia N, et al. Fever Prevention in Patients With Acute Vascular Brain Injury: The INTREPID Randomized Clinical Trial. JAMA. 2024. PMID: 39320879. doi:10.1001/jama.2024.14745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。